Innoviva, Inc. (INVA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 1:20 PM EDT
Company Participants
Pavel Raifeld – CEO & Director
Conference Call Participants
Asad Haider – Goldman Sachs Group, Inc., Research Division
Presentation
Asad Haider
Goldman Sachs Group, Inc., Research Division
All right. Terrific. Let’s go right into our next session. I am very pleased to have Pavel Raifeld, CEO of Innoviva Pharmaceuticals. Pavel, thank you so much for being with us for the afternoon session.
Question-and-Answer Session
Asad Haider
Goldman Sachs Group, Inc., Research Division
So maybe, Pavel, just for investors listening on the webcast and those online and maybe for those not really familiar with the story, let’s just start to level set with a little bit of a brief evolution of the company, its core pillars and what in your view makes Innoviva different.
Pavel Raifeld
CEO & Director
Perfect. Asad, thank you very much. It’s a pleasure to be here, and I appreciate an opportunity to attend the conference. And because of that, I try to spend my time where I think it will benefit our shareholders the most. And our roots are that a number of years ago, we invented the technology that’s being used in some of the most some of the most commonly used asthma and COPD treatments, which have been commercialized by GSK. And we are receiving royalties on those revenues. And so when I joined Innoviva a few years ago, we, in many ways, looked like a pure-play royalty company. And so over time, in our efforts to create value for shareholders, we have built a much more diversified business, which right now has 3 pillars, and I believe that each pillar contributes very meaningfully to the value creation opportunity for Innoviva.
The first one
